Abstract: Disclosed are novel conjugates and processes for the preparation thereof.

Abstract: The present invention relates to novel anti-FLT3 antibodies for specifically targeting extracellular domain of FLT3. The present invention further relates to targeting FLT3 by novel antibody-drug-conjugates (ADCs) based on the novel anti-FLT3 antibodies of the present invention, especially in combination with kinase inhibitors, for use in therapy and/or for use in a method of cancer treatment (e.g., acute myeloid leukemia (AML) with or without internal tandem duplication (ITD) mutations in the FLT3 gene (FLT3-ITD)).

Abstract: Disclosed are novel conjugates and processes for the preparation thereof.

Abstract: The present invention relates to an anti-CD47 antibody or an antigen-binding fragment thereof, comprising variable heavy chain complementarity determining regions 1 to 3 (CDRH1, CDRH2, CDRH3) and variable light chain complementarity determining regions 1 to 3 (CDRL1, CDRL2, CDRL3). The anti-CD47 antibody or an antigen-binding fragment thereof is capable of blocking the interaction of CD47 with signal regulatory protein alpha (SIRPalpha). Further envisaged is an anti-CD47 antibody or antigen-binding fragment combined to a further functional component.

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: Disclosed are novel conjugates and processes for the preparation thereof.

Abstract: Disclosed are novel conjugates and processes for the preparation thereof.

Abstract: The present invention provides means and methods for functionalizing a polypeptide of interest at its C-terminus with an amino acid derivative.

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: The present invention relates to an antibody-drug conjugate (ADC) comprising: (a) Brentuximab, wherein Brentuximab comprises at the C-terminus of the light chains, the heavy chains or all of the heavy and light chains of the Brentuximab a recognition sequence for tubulin tyrosine ligase and a non-natural amino acid; and (b) at least one drug moiety; wherein a drug moiety is coupled to each of the non-natural amino acids via a linker. The present invention further relates to methods of producing same, pharmaceutical compositions comprising same as well as uses thereof.

Abstract: Disclosed are novel conjugates and processes for the preparation thereof.

Abstract: Disclosed are novel conjugates and processes for the preparation thereof. A process tor the preparation of alkene- or alkyne-phosphonamidates comprises the steps of (I) reacting a compound of formula (III), with an azide of formula (IV), to prepare a compound of formula (V), reacting a compound of formula (V) with a thiol-containing molecule of formula (VI), resulting in a compound of formula (VII).

Abstract: The present invention relates to a peptide comprising a reversible affinity tag (A); and a functionalization tag (F), wherein the peptide is linked to a target of interest (T). The peptide is useful as a versatile protein tag. The invention further provides structures comprising the peptide, nucleic acids, vectors, and host cells. Further, the invention provides methods of producing or using the peptide.

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: Disclosed are novel conjugates and processes for the preparation thereof. A process for the preparation of alkene- or alkyne-phosohonothiolates and -phosphonates comprises the step of: reacting a compound of formula (I) with a thiol-containing molecule of formula (II) wherein represents an amino acid, a peptide, a protein, an antibody, a nucleotide, an oligonucleotide, a saccharide, a polysaccharide, a polymer, an optionally substituted C1-C8-alkyl, an optionally substituted phenyl, or an optionally substituted aromatic 5- or 6-membered heterocyclic system; resulting in a compound of formula (III).

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: Disclosed are novel conjugates and processes for the preparation thereof. A process for the preparation of alkene- or alkyne-phosphonamidates comprises the steps of (I) reacting a compound of formula (III), with an azide of formula (IV), to prepare a compound of formula (V), reacting a compound of formula (V) with a thiol-containing molecule of formula (VI), resulting in a compound of formula (VII).

Abstract: The present invention provides means and methods for functionalizing a polypeptide of interest at its C-terminus with an amino acid derivative.